Clinical Trial: Investigating the Safety, Pharmacokinetics, and Preliminary Efficacy of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403643) titled 'Investigating the Safety, Pharmacokinetics, and Preliminary Efficacy of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria' on Feb. 04.

Brief Summary: Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide. It accounts for half of all malaria cases outside Africa, with an estimated 14.3 million clinical vivax malaria cases reported annually, contributing to an annual cost of US$359 million. Children are most vulnerable to infection, with P. vivax prevalence peaking between 2 to 6 years of age. In Papua New Guinea (PNG), there are >1...